Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

XTLB Relative to the S&P 500

XTLB Relative to the Sector

% of Revenue Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the XTL Biopharmaceuticals Ltd. (NASD:XTLB) seasonal charts above shows that a Buy Date of April 20 and a Sell Date of July 29 has resulted in a geometric average return of 1.86% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 13 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 36.54% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

To download XTLB seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: XTLB